TY - JOUR T1 - Alterations of the Retinoblastoma and P16 Pathway Correlate with Promoter Methylation in Malignant Fibrous Histiocytomas JF - Anticancer Research JO - Anticancer Res SP - 3461 LP - 3465 VL - 26 IS - 5A AU - ULRICH BRINCK AU - THILO SCHLOTT AU - STEFFI STÖRBER AU - JERZY STACHURA AU - PAWEL BORTKIEWICZ AU - WOLF-DIETER NAGEL AU - FRANK MICHAEL HASSE AU - CARLOS CORDON-CARDO AU - GÖSTA FISCHER AU - MONIKA KORABIOWSKA Y1 - 2006/09/01 UR - http://ar.iiarjournals.org/content/26/5A/3461.abstract N2 - Recent reports indicate that the alterations in the p16 and pRb pathways can influence tumour progression and poor prognosis in several tumours. The objective of this study was to analyse p16 and pRb expression in161 patients with malignant fibrous histiocytomas (MFH). By immunohistochemistry, p16 and pRb were demonstrated in 25% and 56% of MFH, respectively. Cox regression analysis demonstrated an independent prognostic influence of both genes. Generally, the loss of p16 and pRb expression correlated with poorer prognosis. Promoter methylation of p16 was found in 16/42 of p16 negative MFH and of pRb in 2/42 of pRb-negative MFH. It can be concluded that p16 and pRb alterations play an important role in the progression of soft tissue sarcomas. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -